Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating ...

The advocacy group I AM ALS secured $313 million in federal funding for its campaign to accelerate research and expand access ...

AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical ...

The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...

Amyotrophic Lateral Sclerosis is a neurodegenerative disease that affects the nervous system; around 400,000 people live with ...

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) ...

A Spanish hospital has begun administering a newly approved therapy for patients with a rare genetic form of ALS.

WASHINGTON — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by patients ...

A researcher at the University of Missouri has made a promising breakthrough in the quest to help people with amyotrophic lateral sclerosis (ALS), the neurodegenerative disorder commonly known as Lou ...